BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ipsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ipsen's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06730061-1262@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT06730061)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3\, Primary Biliary Cholangitis.\n
 Study: A Study of Elafibranor in Adult Japanese Participants With Primary 
 Biliary Cholangitis (PBC)\nEstimated primary completion: 17 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06730061
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775485-2192@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT04775485)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: A Study to Evaluate Tov
 orafenib in Pediatric and Young Adult Participants With Relapsed or Progre
 ssive Low-Grade Glioma and Advance Solid Tumors\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tov
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04775485
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05566795-2192@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tovorafenib: Phase 3 readout est. (NCT05566795)
DESCRIPTION:Tovorafenib\, phase 3\, Glioma.\nStudy: DAY101 vs. Standard of 
 Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requirin
 g First-Line Systemic Therapy (LOGGIC/FIREFLY-2)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovo
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05566795
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016842-1262@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT06016842)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3\, Primary Biliary Cholangitis.\n
 Study: A Long-Term Study of Elafibranor in Adult Participants With Primary
  Biliary Cholangitis\nEstimated primary completion: 31 May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06016842
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387549-1262@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT07387549)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3.\nStudy: A Study to Assess How W
 ell and Safely Elafibranor Works in Adult Participants With Primary Sclero
 sing Cholangitis\nEstimated primary completion: 30 April 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07387549
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627362-1262@assetmemo.bio
DTSTAMP:20261121T004012Z
DTSTART;VALUE=DATE:20310923
DTEND;VALUE=DATE:20310924
SUMMARY:Iqirvo (Elafibranor): Phase 2 readout est. (NCT05627362)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 2.\nStudy: A Study to Assess Safet
 y and Effectiveness of Elafibranor in Adult Participants With Primary Scle
 rosing Cholangitis.\nEstimated primary completion: 23 September 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05627362
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
